In order to confirm this relationship and the capacity of dasatinib to inhibit mTOR signaling we exposed primary t(6;9)-AML blasts to dasatinib, ponatinib, Torin1, and BEZ for studying the effects of these inhibitors on LYN and mTOR/AKT activation. The gene discussed is AKT1; the disease is acute myeloid leukemia.